Send to

Choose Destination
Maturitas. 2007 Feb 20;56(2):227-9.

The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy.

Author information

Frederiksberg Hospital, Department of Ob/Gyn, 2000 Copenhagen F, Denmark.


This new statement from EMAS presents the findings reported in recent publications from both WHI trials. In general, the reports do not necessitate a revision of the current EMAS advice. They provide further insight into the ongoing controversy around the possibility that hormone therapy (HT) in the form of estrogen (E) alone or estrogen-progestogen (EP) may influence risk of breast cancer differently. They confirm that the increase of breast cancer diagnosis under EP is only significant after a cumulative use of more than 5 years but suggest that there is no increased risk by E within 10 years.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center